Table 5.

Medication Use During Follow-Up of the Study Patients

Medications During Follow-Up	Stent-Only (n=185)	Balloon-Stent (n=390)	P Value
Patients with a 12-mo visit, n (%)	164 (89%)	345 (88%)	0.95
Aspirin at 12 mo, n (%)	154 (94%)	319 (92%)	0.46
P2Y12 inhibitor at 12 mo, n (%)	146 (89%)	305 (88%)	0.76
Clopidogrel at 12 mo, n (%)	137 (84%)	283 (82%)	0.62
Ticlopidine at 12 mo, n (%)	0 (0%)	1 (0%)	1.00
Prasugrel at 12 mo, n (%)	7 (4%)	13 (4%)	0.78
Other at 12 mo, n (%)	2 (1%)	9 (3%)	0.52
Statin at 12 mo, n (%)	154 (94%)	319 (92%)	0.46
Number of subjects who had a 24-month visit, n (%)	134 (72%)	257 (66%)	0.12
Aspirin at 24 mo, n (%)	125 (93%)	229 (89%)	0.18
P2Y12 inhibitor at 24 mo, n (%)	75 (56%)	151 (59%)	0.60
Clopidogrel at 24 mo, n (%)	71 (53%)	136 (53%)	0.99
Ticlopidine at 24 mo, n (%)	0 (0%)	0 (0%)	N/A
Prasugrel at 24 mo, n (%)	2 (1%)	7 (3%)	0.72
Other at 24 mo, n (%)	2 (1%)	8 (3%)	0.50
Statin at 24 mo, n (%)	124 (93%)	234 (91%)	0.62
Number of subjects who had a 36-mo visit, n (%)	91 (49%)	164 (42%)	0.11
Aspirin at 36 mo, n (%)	81 (89%)	132 (80%)	0.13
P2Y12 inhibitor at 36 mo, n (%)	47 (52%)	68 (41%)	0.15
Clopidogrel at 36 mo, n (%)	41 (45%)	60 (37%)	0.23
Ticlopidine at 36 mo, n (%)	0 (0%)	0 (0%)	N/A
Prasugrel at 36 mo, n (%)	2 (2%)	6 (4%)	0.71
Other at 36 mo, n (%)	4 (4%)	2 (1%)	0.19
Statin at 36 mo, n (%)	81 (89%)	144 (88%)	0.85

N/A indicates not any.